Skip to main content
Premium Trial:

Request an Annual Quote

Myriad RBM, Institut Pasteur to Field Test Platform for TB

NEW YORK (GenomeWeb) – Myriad RBM, a wholly owned subsidiary of Myriad Genetics, today said it is collaborating with Institut Pasteur to field test Myriad RBM's TruCulture as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis. 

Funded by a grant from the Bill & Melinda Gates Foundation to Institut Pasteur, the proof-of-concept study will evaluate patients affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites and who have latent or active TB. Using Myriad RBM's MAP platform, the partners aim to discover protein biomarkers that are crucial in regulating immune system response.

In a statement, Matthew Albert, co-coordinator of Milieu Interieur and director of the immunology department at Institut Pasteur, said that earlier studies support the use of the TruCulture system in settings with limited resources, "and may help us improve the diagnosis of TB and accelerate the development of new drugs and vaccines to treat the disease." 

The TruCulture system captures immune cell activity and uses a single, self-contained tube for whole blood collection and culture. 

Myriad RBM President Ralph McDade added that the collaboration will result in better treatments and better support for vaccine clinical trials. "If we are successful, TruCulture may prove to be useful in a multitude of field-based, point-of-care applications, leading to improved patient care," he said. 

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.